Common Contracts
2 similar Clinical Trial Agreement contracts
CLINICAL TRIAL AGREEMENT FOR PROTOCOL GS-US-592-6238Clinical Trial Agreement • January 19th, 2023
Východoslovenský Onkologickyý Ústav a.s., a hospital with an address at Rastislavova 43, 041 91 Košice, Slovak republic (the “Institution”),
CLINICAL TRIAL AGREEMENT FOR PROTOCOL GS-US-592-6238Clinical Trial Agreement • November 25th, 2022
and Gilead Sciences, Inc., a Delaware corporation with headquarters located at xxxxxxxx “Gilead”), in connection with a clinical trial conducted pursuant to Protocol GS-US-592-6238, “A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD- L1 or in Patients Previously Treated With Anti-PD- (L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1” (together with any amendments thereto, which are incorporated herein by reference, the “Protocol”) (the “Trial”), at Institution’s Bratislava, Slovak republic location (“Trial Site”). The effective date of this Agreement (the “Effective Date”) shall be the date following the date on which the Agreement is registered in the Central Registry of Contracts (“Centrálný Register Zmlúv”). The Trial will be conducted under the immediate supervision of the In
